This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Bioverativ Inc.
Bioverativ Inc., a leading biotechnology company headquartered in the United States, focuses on developing innovative therapies for patients with rare blood disorders, particularly haemophilia. Founded in 2017, Bioverativ has quickly established itself in the biopharmaceutical industry, achieving significant milestones such as the successful launch of its flagship products, Eloctate and Alprolix, which offer extended protection for individuals with haemophilia A and B. With a commitment to advancing treatment options, Bioverativ's unique approach combines cutting-edge science with patient-centric solutions, positioning the company as a key player in the global market. The firm operates primarily in North America and Europe, striving to improve the quality of life for those affected by these conditions. Through its dedication to research and development, Bioverativ continues to make notable contributions to the field of haemophilia care.
DitchCarbon Score
How does Bioverativ Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bioverativ Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bioverativ Inc., headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported emissions figures. The company is a current subsidiary of Sanofi, and any climate commitments or emissions data would be cascaded from its parent organisation. Sanofi has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, which focuses on renewable energy commitments. However, specific reduction targets or achievements for Bioverativ Inc. have not been detailed in the available information. As a subsidiary, Bioverativ's climate commitments are likely aligned with Sanofi's broader sustainability goals, which aim to reduce greenhouse gas emissions across all scopes. The lack of direct emissions data suggests that Bioverativ is in the process of developing its own climate strategy, potentially influenced by the initiatives and targets set by Sanofi.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bioverativ Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
